Article Information
History
- June 7, 2024.
Article Versions
- Version 1 (April 2, 2022 - 14:09).
- Version 2 (July 12, 2023 - 12:30).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ekkehard Hewer1,2,*,
- Pascal Fischer1,
- Erik Vassella1,
- Laura Knabben4,
- Sara Imboden4,
- Michael D. Mueller4,
- Tilman T. Rau1,3 and
- Matthias S. Dettmer1,5,*
- 1Institute of Pathology, University of Bern, Bern, Switzerland
- 2Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- 3Institute of Pathology, Heinrich-Heine-University and University Hospital Duesseldorf, Düsseldorf, Germany
- 4Department of Gynaecology and Obstetrics, Inselspital University Hospital, Bern, Switzerland
- 5Institute of Pathology, Klinikum Stuttgart, Stuttgart, Germany
- ↵*Correspondence to: Ekkehard Hewer, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 25, CH-1011 Lausanne; ekkehard.hewer{at}unil.ch or Matthias S. Dettmer, Institute of Pathology, Klinikum Stuttgart, Kriegsbergstraße 60, 70174 Stuttgart, Germany; m.dettmer{at}klinikum-stuttgart.de
Posted June 07, 2024.
Lymphoid Enhancer-Binding Factor 1 (LEF1) immunostaining as a surrogate of β-catenin (CTNNB1) mutations
